• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Stock The SCTR Report: Insmed’s Stock Hangs in the Balance—Here’s What You Need to Know
Stock

The SCTR Report: Insmed’s Stock Hangs in the Balance—Here’s What You Need to Know

by September 12, 2024
by September 12, 2024 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

Numerous companies are making strides within their respective sectors, but, unless you follow the sector closely, you might not be aware of them. That’s what makes StockCharts Technical Rank (SCTR) reports so helpful.

If you’ve checked your SCTR reports regularly, you might have noticed Insmed (INSM) appear at or near the top over the last three months.

FIGURE 1. DAILY SCTR REPORTS SHOW INSM IN THE OF THE TOP-UP, LARGE-CAP STOCKS.Image source: StockCharts.com. For educational purposes.

Insmed (INSM) is a biotech company that has had a near-perfect SCTR score of 99.9 since the end of May.

A SCTR (pronounced scooter) score above 90 is exceedingly bullish, as it signals technical strength across multiple technical indicators and timeframes. Sustaining a score well above 90 for months tells you that something tremendous is happening with the company and its stock.

But if you don’t follow biotech, you’re probably wondering, “What is Insmed? Why haven’t I heard of it? Why is it soaring now? Where was it before it showed up on the SCTR report’s top spot?”

In a Nutshell, Here’s What’s Driving INSM

Insmed’s stock is popping thanks to positive results from a late-stage study of its antibiotic drug Arikayce, developed for treating a rare, severe lung infection. The study’s success boosts hopes for broader FDA approval, driving INSM’s sharp breakaway gap to all-time highs.

Before this, however, what did INSM’s performance look like?

Three-Year Lookback at INSM’s Performance

FIGURE 2. WEEKLY CHART OF INSM. The recent tests catapulted INSM to all-time highs.Chart source: StockCharts.com. For educational purposes.

Take note of the following points:

The breakaway gap (see orange short-term downsloping trend line) from $22 to $49.53 marked a 125% spike.While INSM’s SCTR score has exceeded the 90 line four times in the last three years (see green circles), notice how it barely outperformed, and largely underperformed, its broader industry, represented by the Dow Jones U.S. Biotechnology Index ($DJUSBT).The latest break above the 90 line looks flat-out bullish (see green rectangle), aligning with a 171% outperformance of its industry.

Does this make INSM a strong candidate for a long position? To explore that further, let’s shift to a daily chart.

Should You Go Long INSM?

FIGURE 3. DAILY CHART OF INSM. Note the declining momentum and topping formation.Chart source: StockCharts.com. For educational purposes.

Here are the main things to keep an eye on:

INSM looks to be forming a double top; still, market sentiment reacting to INSM’s latest testing news and developments moving forth may defy (bearish) technical indications.The Chaikin Money Flow (CMF) shows that buying pressure is fading, matching up with the Relative Strength Index’s (RSI’s) bearish divergence signal from overbought levels.Despite looking toppy, for INSM’s near-term uptrend to continue, you’d want to see it break above resistance at its all-time level of $80.53 while remaining above its most recent swing low at the $70 range.If it falls below the $70 range, the next lines of support can be at the previous swing lows of $67.20 and $61.50.

Warning: A deeper correction may indicate that something is off between the technical reading and the market’s reaction to the company’s news or product development.

If INSM falls below $61.50, the long-term uptrend could still hold despite invalidating the short-term trend. Be extra careful, though! INSM might slide to $45–$52, hitting key Fibonacci retracement levels, but a dip that low could mean something big has changed with INSM’s product development, and the price action may be reflecting the market’s response to these (bearish) developments.

Closing Bell

StockCharts’ SCTR Reports spotlight hidden stock opportunities that might not have crossed your radar. Insmed is a great example. It’s been riding high on positive testing news, but its technicals are flashing warning signs. If you want to follow INSM’s price action, add it to one of your StockCharts ChartLists. If not, be sure to use SCTR daily to find other (potentially hidden) opportunities for your next trade.

Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

You Might Also Like
  • Equities Remain in Strong “Go” Trend, Edging Ever Higher
  • DP Trading Room: Is Broadcom (AVGO) the New NVIDA (NVDA)?
  • DP Trading Room: Why SPY, Not SPX? Dividends!
  • Stocks In Focus This Week: Palantir, Uber, and Coinbase
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Caroline Ellison seeks to duck prison sentence for role in FTX collapse
next post
Trump Media shares sink to new post-merger low after presidential debate

You may also like

Stock Market Makes Spectacular Run, and It’s Not From the...

July 12, 2024

New Highs Coming or Will We Collapse? What Say You,...

July 26, 2024

Why Investors are Betting Big on Berkshire Hathaway Class B...

June 26, 2024

Identifying Top Charts with Upside Potential in 2024

July 9, 2024

Best Way to Capitalize on Election Rally!

November 9, 2024

2-Year Business Cycles Matter in This Market

February 8, 2023

AMZN: A Case Study in Bearish Divergence

February 24, 2025

These Groups Just Turned BULLISH!

August 19, 2024

$4,000 Gold? Analysts Eye New Highs on Inflation and Geopolitical...

April 22, 2025

Fearless Rotation Back To Growth Stocks Is Unfolding Now

March 17, 2023

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Nvidia results spark global chip rally

      May 30, 2025
    • Boeing to resume airplane deliveries to China next month, ramp up Max production, CEO says

      May 29, 2025
    • Nuclear Power Trio: OKLO, SMR, and CCJ in Focus

      May 29, 2025
    • Analyzing SIL, USO, and NVDA: Could These Bullish Patterns Trigger?

      May 29, 2025
    • E.l.f. Beauty to acquire Hailey Bieber skin care brand Rhode in up to $1 billion deal

      May 29, 2025

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,764 views
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,470 views
    • 3

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 2,450 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,429 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,307 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,104)
    • Investing (538)
    • Stock (2,578)

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 3

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Nvidia results spark global chip rally

      May 30, 2025
    • Boeing to resume airplane deliveries to China next month, ramp...

      May 29, 2025
    • Nuclear Power Trio: OKLO, SMR, and CCJ in Focus

      May 29, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,104)
    • Investing (538)
    • Stock (2,578)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    How to Use ADX to Find...

    June 8, 2023

    Sector Spotlight: Decoding The S&P’s Monthly...

    November 28, 2023

    Microsoft (MSFT) Stock On the Verge...

    October 25, 2023
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here